Ending Drama, Medicare Will Cover RedPath's PathFinderTG Pancreatic Cancer Dx in Four States

Beginning Nov. 5, Medicare will cover the platform as a “reasonable and necessary” service for analyzing pancreatic cysts and masses "when traditional Dx evaluations are inconclusive." The coverage also includes Washington, DC.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.